Form 4: Eterna Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
David Polinsky, a Director of Eterna Therapeutics Inc., received 5,083 shares of common stock on August 31, 2026.
Summary
- Grant/award: acquired 5,083 Stock Option (Right to buy) on August 31, 2026; holds 5,083 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Polinsky — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-31 | Grant/award | Stock Option (Right to buy) | 5,083 | — | — | 5,083 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-31 | Grant/award (5,083 shares) |
Keywords
insider transaction, Form 4, ERNA, Ernexa Therapeutics Inc., neutral, David Polinsky
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.